Anyvia Tablets 100 mg (Sitagliptin Hydrochloride Monohydrate)
Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Kujoo Pharmaceutical Co., Ltd.
MFDS item code 202004059 · Approved 2020.05.29
This product's status changed to Expired on 2025.05.29. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used to help control blood sugar levels in patients with type 2 diabetes. It can be administered alone when starting treatment. However, if blood sugar control is difficult with initial monotherapy, it can be taken in conjunction with metformin. Additionally, when sufficient blood sugar control is not achieved with existing therapies using sulfonylureas, metformin, thiazolidinediones, or insulin, this medication may be added for combination therapy. Furthermore, when multiple medications are used and blood sugar control is still inadequate, this medication can be used together to enhance effectiveness. In summary, this medication is used either alone or in combination with other antidiabetic drugs to improve blood sugar control in patients with type 2 diabetes.
For monotherapy or combination therapy, administer 100 mg of sitagliptin once daily; the maximum daily dose is 100 mg. This medicine may be taken with or without food. When used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, section 5. General Precautions). Patients with renal impairment Because dosage adjustment according to renal function is required, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dosage adjustment is required in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is required in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered regardless of the timing of dialysis.
This medication is an antidiabetic agent made with the ingredient sitagliptin. First, caution should be taken as serious allergic reactions may occur while taking this medication, including anaphylaxis, angioedema, and severe skin rashes or exfoliative skin disorders. If such symptoms occur, stop taking the medication immediately and visit a hospital. Second, there is a risk of pancreatitis (inflammation of the pancreas). If symptoms such as abdominal pain, vomiting, or severe abdominal discomfort occur after taking this medication, consult a doctor immediately. Third, this medication is not used in patients with type 1 diabetes or diabetic ketoacidosis. Fourth, patients with impaired kidney function may need dose adjustments, and regular kidney function tests are important. Fifth, when used in conjunction with insulin or sulfonylurea medications, there may be an increased risk of hypoglycemia, so careful monitoring of blood sugar changes is necessary. Sixth, long-term use may result in side effects such as headache, upper respiratory infection, nasopharyngitis, diarrhea, nausea, and persistent symptoms should be discussed with a doctor. Seventh, it is recommended that pregnant or breastfeeding women avoid using this medication. Eighth, in case of overdose, visit a medical institution immediately for appropriate treatment and monitoring. Blood dialysis may be considered if necessary. Finally, while this medication is known not to increase cardiovascular disease risk even with long-term use, elderly patients or those with impaired kidney function should be more cautious.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air exposure, and it is best to store it at room temperature between 1 and 30 degrees Celsius. This will help maintain the medication's effectiveness.
Light orange, round, biconvex film-coated tablet
28 tablets) 14 tablets/PTP (x2), 30 tablets) 10 tablets/PTP (x3)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Kujoo Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Korea United Pharm., Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 28.35mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 56.7mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.